Replies to post #86634 on Biotech Values

[DewDiligence]

ghmm et al re MNTA: Another silly portion of the latest analyst report is this (from #msg-43844899):

The Markman hearing for Copaxone litigation, which has been anticipated for December, has not been scheduled yet and may occur in January.

The analyst tries to characterize a delay that has not even occurred yet as a reason for downgrading the stock! This is especially silly because the exact timing of the Markman hearing* is not a major concern for MNTA shareholders. Regardless of whether the hearing occurs in December or occurs in January, the Copaxone litigation is going to continue for a long time. In the overall scheme of things, the precise scheduling of the Markman hearing is inconsequential.

*The Markman hearing is the pre-trial conference in which the judge establishes the technical meaning of the claims in the disputed patents.